A Phase 3 interventional study of Inclisiran Sodium for injection and Placebo in Homozygous Familial Hypercholesterolemia, sponsored by Novartis Pharmaceuticals. Completed at 13 sites in 8 countries. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-30.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study was a Phase III,A two-part (double-blind placebo-controlled/open-label) multicenter study to evaluate safety, tolerability, and efficacy of inclisiran in subjects with homozygous familial hypercholesterolemia (HoFH).
This study had two sequential parts:
68 studies on the registry are indexed under Homozygous Familial Hypercholesterolemia; 13 are open to participants now.
This study's enrollment of 56 is above the median of 21 across 51 interventional studies indexed under Homozygous Familial Hypercholesterolemia.
Browse Homozygous Familial Hypercholesterolemia studies →Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Females who are pregnant or nursing, or who are of and unwilling to use at least one acceptable effective method of (eg, oral contraceptives, barrier methods, approved contraceptive implant, long- term injectable contraception, intrauterine device) for the entire duration of the study. Exemptions from this criterion:
Any condition that according to the investigator could interfere with the conduct of the study, such as but not limited to:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who received a dose of 300 milligram (mg) inclisiran sodium for injection administered by SC injection on Day 1 and Day 90.
Drug: Inclisiran Sodium for injection
Participants who received a dose of placebos administered by SC injection on Day 1 and Day 90.
Drug: Placebo · Drug: Placebos
Participants who received a dose of 300 mg inclisiran sodium for injection administered by SC injection on Day 270, Day 450 and Day 630. In addition, participants who were assigned to the placebo arm in Part 1 will receive a dose of 300 mg inclisiran sodium administered by SC injection on Day 180 after completion of Part 1.
Drug: Inclisiran Sodium for injection
Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.
Also known as: ALN-PCSSC; KJX839, ALN-PCSSC
Sterile normal saline (0.9% sodium chloride in water for injection)
Sterile normal saline (0.9% sodium chloride in water for injection)
Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 150
Percentage Change in LDL-C levels from Baseline to Day 150
Time frame: Baseline, Day 150
Absolute Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 150
Absolute Change in LDL-C levels (mg/dL) from baseline to Day 150
Time frame: Baseline, Day 150
Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Subsequent Visits up to Day 180
Percentage Change in LDL-C levels from baseline to subsequent visits on Days 90, 150, and 180
Time frame: Baseline, Days 90, 150, 180
Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Subsequent Visits up to Day 720
Percentage Change in LDL-C levels from baseline to subsequent visits up to Day 720
Time frame: Baseline, Days 270, 330, 450, 510, 630, 690, and 720
Absolute Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Subsequent Visits up to Day 180
Absolute change in LDL-C levels (mg/dL) from baseline to subsequent visits on Days 90, 150 and 180 based on the
Time frame: Baseline, Days 90, 150, 180
Absolute Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Subsequent Visits up to Day 720
Absolute change in LDL-C levels from Baseline to Subsequent Visits up to Day 720
Time frame: Baseline, Days 270, 330, 450, 510, 630, 690, and 720
Percent Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) From Baseline to Subsequent Visits up to Day 180
Percentage Change in PCSK9 from baseline to subsequent visits up to Day 180
Time frame: Baseline, Days 90, 150, 180
Percent Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) From Baseline to Subsequent Visits up to Day 720
Percentage Change in PCSK9 from baseline to subsequent visits up to Day 720
Time frame: Baseline, Days 270, 330, 450, 510, 630, 690, and 720
Absolute Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) From Baseline to Subsequent Visits up to Day 180
Absolute Change in PCSK9 from baseline to subsequent visits up to Day 180
Time frame: Baseline, Days 90, 150, 180
Absolute Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) From Baseline to Subsequent Visits up to Day 720
Absolute Change in PCSK9 from baseline to subsequent visits up to Day 720
Time frame: Baseline, Days 270, 330, 450, 510, 630, 690, and 720
Percent Change in Total Cholesterol From Baseline to Subsequent Visits up to Day 180
Percentage change in total cholesterol from baseline to subsequent visits up to Day 180
Time frame: Baseline, Days 90, 150 and 180
Absolute Change in Total Cholesterol From Baseline to Subsequent Visits up to Day 180
Absolute Change in total cholesterol from baseline to subsequent visits up to Day 180
Time frame: Baseline, Days 90, 150, 180
Percent Change in Total Cholesterol From Baseline to Subsequent Visits up to Day 720
Percentage change in total cholesterol from baseline to subsequent visits up to Day 720
Time frame: Baseline, Days 270, 330, 450, 510, 630, 690, and 720
Absolute Change in Total Cholesterol From Baseline to Subsequent Visits up to Day 720
Absolute Change in total cholesterol from baseline to subsequent visits up to Day 720
Time frame: Baseline, Days 270, 330, 450, 510, 630, 690, and 720
Percent Change in Apolipoprotein B (apoB) From Baseline to Subsequent Visits up to Day 180
Percentage change in Apolipoprotein B (apoB) from baseline to subsequent visits up to Day 180 demonstrated by Mixed Model Repeated Measures statisitical method.
Time frame: Baseline, Days 90, 150, 180
Percent Change in Apolipoprotein B (apoB) From Baseline to Subsequent Visits up to Day 720
Percentage Change in Apolipoprotein B (apoB) from baseline to subsequent visits up to Day 720
Time frame: Baseline, Days 270, 330, 450, 510, 630, 690, and 720
Absolute Change in Apolipoprotein B (apoB) From Baseline to Subsequent Visits up to Day 180
Absolute change in Apolipoprotein B (apoB) from baseline to subsequent visits up to Day 180
Time frame: Baseline, Days 90, 150, 180
Absolute Change in Apolipoprotein B (Apo B) From Baseline to Subsequent Visits up to Day 720
Absolute Change in Apolipoprotein B (Apo B) from baseline to subsequent visits up to Day 720
Time frame: Baseline, Days 270, 330, 450, 510, 630, 690, and 720
Percent Change in Non-HDL Cholesterol (Non-HDL-C) From Baseline to Subsequent Visits up to Day 180
Percentage change in non-HDL-C levels from baseline to subsequent visits up to Day 180
Time frame: Baseline, Days 90, 150, 180
Percent Change in Non-HDL Cholesterol (Non-HDL-C) From Baseline to Subsequent Visits up to Day 720
Percentage Change in non-HDL-C from Baseline to subsequent visits up to Day 720
Time frame: Baseline, Days 270, 330, 450, 510, 630, 690, and 720
Absolute Change in Non-HDL Cholesterol (Non-HDL-C) From Baseline to Subsequent Visits up to Day 180
Absolute change in non-HDL-C levels from Baseline to subsequent visits up to Day 180
Time frame: Baseline, Days 90, 150, 180
Absolute Change in Non-HDL Cholesterol (Non-HDL-C) From Baseline to Subsequent Visits up to Day 720
Absolute Change in non-HDL Cholesterol (non-HDL-C) from Baseline to Subsequent Visits up to Day 720
Time frame: Baseline, Days 270, 330, 450, 510, 630, 690, and 720
Individual Responsiveness of Subjects: Part 1
Individual Responsiveness of Subjects defined as the number of subjects reaching on treatment LDL-C levels of \<25 mg/dL, \<50 mg/dL, \<70 mg/dL, and \<100 mg/dL up to Day 180
Time frame: Days 150, 180
Individual Responsiveness of Subjects: Part 2
Individual Responsiveness of Subjects defined as the number of subjects reaching on treatment LDL-C levels of \<25 mg/dL, \<50 mg/dL, \<70 mg/dL, and \<100 mg/dL up to Day 720
Time frame: Days 330, 510, 690 and 720
Proportional Responsiveness: Part 1
Number of participants in each group who attain global lipid targets for their indication
Time frame: Days 150, 180
Proportional Responsiveness of Subjects: Part 2
Number of participants in each group who attain global lipid targets for their indication
Time frame: Days 330, 510, 690 and 720
LDL-C Reduction ≥20% or ≥30% From Baseline: Part 1
Proportion of subjects in each group with ≥20% or ≥30% LDL-C reduction from Baseline in Part 1 (Days 90, 150, 180)
Time frame: Baseline, Days 90, 150, 180
LDL-C Reduction ≥20% or ≥30% From Baseline: Part 2
Proportion of subjects in each group with ≥20% or ≥30% LDL-C reduction from Baseline in Part 2 (Days 330, 510, 690, and 720)
Time frame: Baseline, Days 330, 510, 690, and 720
Percent Change in High-Density Lipoprotein Cholesterol Levels (HDL-C) From Baseline to Subsequent Visits up to Day 180
Percentage Change in HDL-C levels (mg/dL) from baseline to subsequent visits on Day 90, 150, and 180
Time frame: Baseline, Days 90, 150, 180
Percent Change in High-Density Lipoprotein Cholesterol Levels (HDL-C) From Baseline to Subsequent Visits up to Day 720
Percentage change in LDL-C levels from Baseline to Subsequent Visits up to Day 720
Time frame: Baseline, Days 330, 450, 510, 630, 690, and 720
Absolute Change in High-Density Lipoprotein Cholesterol Levels (HDL-C) From Baseline to Subsequent Visits up to Day 180
Absolute Change in HDL-C levels (mg/dL) from baseline to subsequent visits on Day 90, 150, and 180
Time frame: Baseline, Days 90, 150, 180
Absolute Change in High-Density Lipoprotein Cholesterol Levels (HDL-C) From Baseline to Subsequent Visits up to Day 720
Absolute change in LDL-C levels from Baseline to Subsequent Visits up to Day 720
Time frame: Baseline, Days 330, 450, 510, 630, 690, and 720
Absolute Change in Very-Low-Density Lipoprotein Cholesterol (VLDL-C) From Baseline to Subsequent Visits up to Day 180
Absolute Change in VLDL-C levels from baseline to subsequent visits on Days 90, 150, and 180
Time frame: Baseline, Days 90, 150, 180
Absolute Change in Very-Low-Density-Lipoprotein Cholesterol Levels (VLDL-C) From Baseline to Subsequent Visits up to Day 720
Absolute change in VLDL-C levels from Baseline to Subsequent Visits up to Day 720
Time frame: Baseline, Days 330, 450, 510, 630, 690, and 720
Percent Change in Very-Low-Density Lipoprotein Cholesterol (VLDL-C) From Baseline to Subsequent Visits up to Day 180
Percentage Change in VLDL-C levels (mg/dL) from baseline to subsequent visits on Days 90, 150, and 180
Time frame: Baseline, Days 90, 150, 180
Percent Change in Very-Low-Density-Lipoprotein Cholesterol Levels (VLDL-C) From Baseline to Subsequent Visits up to Day 720
Percentage change in VLDL-C levels from Baseline to Subsequent Visits up to Day 720
Time frame: Baseline, Days 330, 450, 510, 630, 690, and 720
Absolute Change in Apolipoprotein A-1 (Apo-A1) mg/dL From Baseline to Subsequent Visits up to Day 180
Absolute Change in Apolipoprotein A-1 (Apo-A1) from baseline to subsequent visits on Days 90, 150, and 180
Time frame: Baseline, Days 90, 150, 180
Absolute Change Apolipoprotein A-1 (Apo-A1) From Baseline to Subsequent Visits up to Day 720
Absolute change in Apolipoprotein A-1 (Apo-A1) from Baseline to Subsequent Visits up to Day 720
Time frame: Baseline, Days 330, 450, 510, 630, 690, and 720
Percent Change in Apolipoprotein A-1 (Apo-A1) From Baseline to Subsequent Visits up to Day 180
Percentage Change in Apolipoprotein A-1 (Apo-A1) from baseline to subsequent visits on Day 90, 150, and 180
Time frame: Baseline, Days 90, 150, 180
Percent Change Apolipoprotein A-1 (Apo-A1) From Baseline to Subsequent Visits up to Day 720
Percentage change in Apolipoprotein A-1 (Apo-A1) from Baseline to Subsequent Visits up to Day 720
Time frame: Baseline, Days 330, 450, 510, 630, 690, and 720
Percent Change in Lipoprotein(a) [Lp(a)] From Baseline to Subsequent Visits up to Day 180
Percentage Change in Lp(a) from Baseline to Subsequent Visits up to Day 180
Time frame: Baseline, Days 90, 150, 180
Percent Change in Lipoprotein(a) [Lp(a)] From Baseline to Subsequent Visits up to Day 720
Percentage change in Lp(a) from Baseline to Subsequent Visits up to Day 720
Time frame: Baseline, Days 330, 450, 510, 630, 690, and 720
Absolute Change in Lipoprotein(a) [Lp(a)] From Baseline to Subsequent Visits up to Day 180
Absolute Change in Lp(a) from baseline to subsequent visits up to Day 180
Time frame: Baseline, Days 90, 150, 180
Absolute Change in Lipoprotein(a) [Lp(a)] From Baseline to Subsequent Visits up to Day 720
Absolute change in Lp(a) from Baseline to Subsequent Visits up to Day 720
Time frame: Baseline, Days 330, 450, 510, 630, 690, and 720
Percent Change in High-Sensitivity C-Reactive Protein (hsCRP) From Baseline to Subsequent Visits up to Day 180: Part 1
Percent change in hsCRP from Baseline to subsequent visits up to Day 180
Time frame: Baseline, Days 90, 150, 180
Percent Change in High-Sensitivity C-Reactive Protein (hsCRP) From Baseline to Subsequent Visits up to Day 720: Part 2
Percentage change in hsCRP from baseline to subsequent visits up to Day 720
Time frame: Baseline, Days 330, 510 ,690, 720
Absolute Change in High-Sensitivity C-Reactive Protein (hsCRP) From Baseline to Subsequent Visits up to Day 180: Part 1
Absolute Change in High-Sensitivity C-Reactive Protein (hsCRP) from Baseline to subsequent visits up to Day 180
Time frame: Baseline, Days 90, 150, 180
Absolute Change in High-Sensitivity C-Reactive Protein (hsCRP) From Baseline to Subsequent Visits up to Day 720: Part 2
Absolute Change in High-Sensitivity C-Reactive Protein (hsCRP) from baseline to subsequent visits up to Day 720
Time frame: Baseline, Days 330, 510, 690, 720
Percent Change in Apo-B From Baseline to Day 150
Percentage change in Apo-B from baseline to Day 150 as demonstrated using the ANCOVA statisitical model.
Time frame: Baseline, Day 150
Percent Change in Non-HDL-C From Baseline to Day 150
Percentage Change in non-HDL-C from baseline to Day 150 as demonstrated using the ANCOVA statisitical model.
Time frame: Baseline, Day 150
Percent Change in Total Cholesterol From Baseline to Day 150
Percentage change in total cholesterol from baseline to Day 150 as demonstrated using the ANCOVA statisitical model.
Time frame: Baseline, Day 150
Proportion of Subjects With ≥30% LDL-C Reduction of From Baseline at Day 150
Number of participants in each group with ≥30% LDL-C reduction from baseline at Day 150 using the Regression Logistic Statistical Model
Time frame: Baseline, Day 150
Overall, 56 subjects were enrolled and 53 subjects completed through Day 180 (Part 1) and went into the Open-Label period (Part 2), in which 47 subjects completed.
| Milestone | Part 1 - Inclisiran | Part 1 - Placebo | Part 2 - Placebo-Inclisiran | Part 2 - Inclisiran-Inclisiran |
|---|---|---|---|---|
| Started | 37 | 19 | 0 | 0 |
| Completed | 34 | 19 | 0 | 0 |
| Not completed | 3 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 | 0 | 0 |
| Withdrew: Other reason | 1 | 0 | 0 | 0 |
| Milestone | Part 1 - Inclisiran | Part 1 - Placebo | Part 2 - Placebo-Inclisiran | Part 2 - Inclisiran-Inclisiran |
|---|---|---|---|---|
| Started | 0 | 0 | 34 | 19 |
| Completed | 0 | 0 | 29 | 18 |
| Not completed | 0 | 0 | 5 | 1 |
| Withdrew: Other reason | 0 | 0 | 0 | 1 |
| Withdrew: Death | 0 | 0 | 3 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 2 | 0 |
Percentage Change in LDL-C levels from Baseline to Day 150
| Percentage change | Part 1 - Placebo | Part 1 - Inclisiran |
|---|---|---|
| Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 150 | 2.39 (-19.98 to 24.75) | 0.70 (-14.03 to 15.44) |
Absolute Change in LDL-C levels (mg/dL) from baseline to Day 150
| mg/dL | Part 1 - Placebo | Part 1 - Inclisiran |
|---|---|---|
| Absolute Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 150 | -8.82 (-75.19 to 57.55) | -2.35 (-36.34 to 31.63) |
Percentage Change in LDL-C levels from baseline to subsequent visits on Days 90, 150, and 180
| Percentage change | Part 1 - Placebo | Part 1 - Inclisiran |
|---|---|---|
| Day 90 | 3.3 (-13.0 to 19.6) | -8.7 (-20.3 to 2.8) |
| Day 150 | -2.9 (-22.6 to 16.9) | 1.8 (-12.5 to 16.1) |
| Day 180 | -1.5 (-17.0 to 14.1) | -7.2 (-19.0 to 4.6) |
Percentage Change in LDL-C levels from baseline to subsequent visits up to Day 720
| Percentage change | Part 2 - Placebo-Inclisiran | Part 2 - Inclisiran-Inclisiran |
|---|---|---|
| Day 270 | -10.1 ± 41.62 | -9.1 ± 33.99 |
| Day 330 | -14.4 ± 32.62 | -4.8 ± 50.45 |
| Day 450 | -6.7 ± 26.69 | -4.7 ± 46.92 |
| Day 510 | -9.3 ± 29.52 | 2.4 ± 61.70 |
| Day 630 | -16.6 ± 20.45 | -6.6 ± 43.75 |
| Day 690 | -8.7 ± 32.17 | -4.2 ± 42.39 |
| Day 720 | -14.6 ± 26.11 | -6.2 ± 47.29 |
Absolute change in LDL-C levels (mg/dL) from baseline to subsequent visits on Days 90, 150 and 180 based on the
| mg/dL | Part 1 - Placebo | Part 1 - Inclisiran |
|---|---|---|
| Day 90 | 3.6 (-39.6 to 46.8) | -16.3 (-47.0 to 14.4) |
| Day 150 | -17.2 (-70.8 to 36.3) | 0.5 (-38.3 to 39.2) |
| Day 180 | -7.0 (-50.5 to 36.4) | -14.5 (-47.5 to 18.5) |
Absolute change in LDL-C levels from Baseline to Subsequent Visits up to Day 720
| mg/dL | Part 2 - Placebo-Inclisiran | Part 2 - Inclisiran-Inclisiran |
|---|---|---|
| Day 270 | -27.3 ± 154.94 | -17.5 ± 85.85 |
| Day 330 | -37.2 ± 123.09 | -17.9 ± 113.10 |
| Day 450 | -12.3 ± 108.49 | -19.8 ± 111.41 |
| Day 510 | -20.9 ± 118.05 | -2.2 ± 127.13 |
| Day 630 | -50.5 ± 70.47 | -14.9 ± 107.90 |
| Day 690 | -27.9 ± 115.46 | -8.6 ± 112.93 |
| Day 720 | -43.5 ± 92.99 | -11.0 ± 124.27 |
Percentage Change in PCSK9 from baseline to subsequent visits up to Day 180
| Percentage change | Part 1 - Placebo | Part 1 - Inclisiran |
|---|---|---|
| Day 90 | 9.1 (-5.1 to 23.3) | -53.5 (-63.6 to -43.3) |
| Day 150 | 4.1 (-14.3 to 22.6) | -56.5 (-69.9 to -43.1) |
| Day 180 | 39.2 (17.0 to 61.5) | -53.1 (-70.2 to -35.9) |
Percentage Change in PCSK9 from baseline to subsequent visits up to Day 720
| Percentage Change | Part 2 - Placebo-Inclisiran | Part 2 - Inclisiran-Inclisiran |
|---|---|---|
| Day 270 | -21.5 ± 55.71 | -14.4 ± 160.60 |
| Day 330 | -42.6 ± 32.08 | -57.0 ± 30.36 |
| Day 450 | -35.8 ± 37.55 | -51.1 ± 27.90 |
| Day 510 | -54.0 ± 23.62 | -59.4 ± 24.13 |
| Day 630 | -41.7 ± 29.19 | -48.1 ± 32.65 |
| Day 690 | -48.3 ± 22.30 | -64.3 ± 11.21 |
| Day 720 | -53.8 ± 16.66 | -57.6 ± 39.76 |
Absolute Change in PCSK9 from baseline to subsequent visits up to Day 180
| ug/L | Part 1 - Placebo | Part 1 - Inclisiran |
|---|---|---|
| Day 90 | -25.8 (-110.3 to 58.6) | -342.5 (-403.0 to -282.0) |
| Day 150 | -30.7 (-114.4 to 52.9) | -335.2 (-396.1 to -274.3) |
| Day 180 | 88.8 (-1.2 to 178.9) | -301.5 (-371.4 to -231.7) |
Absolute Change in PCSK9 from baseline to subsequent visits up to Day 720
| ug/L | Part 2 - Placebo-Inclisiran | Part 2 - Inclisiran-Inclisiran |
|---|---|---|
| Day 270 | -174.7 ± 252.10 | -234.4 ± 242.25 |
| Day 330 | -232.1 ± 193.51 | -392.0 ± 422.93 |
| Day 450 | -237.5 ± 199.34 | -387.6 ± 483.81 |
| Day 510 | -304.8 ± 181.41 | -381.0 ± 261.04 |
| Day 630 | -243.6 ± 201.07 | -303.1 ± 200.37 |
| Day 690 | -275.5 ± 163.85 | -441.8 ± 278.87 |
| Day 720 | -296.8 ± 171.96 | -413.2 ± 460.33 |
Percentage change in total cholesterol from baseline to subsequent visits up to Day 180
| Percentage Change | Part 1 - Placebo | Part 1 - Inclisiran |
|---|---|---|
| Day 90 | 2.0 (-11.0 to 14.9) | -5.9 (-15.1 to 3.3) |
| Day 150 | -1.5 (-17.2 to 14.1) | 1.2 (-10.1 to 12.5) |
| Day 180 | -1.4 (-13.8 to 11.0) | -4.9 (-14.3 to 4.5) |
Absolute Change in total cholesterol from baseline to subsequent visits up to Day 180
| mg/dL | Part 1 - Placebo | Part 1 - Inclisiran |
|---|---|---|
| Day 90 | 3.9 (-40.6 to 48.4) | -15.1 (-46.7 to 16.4) |
| Day 150 | -10.5 (-65.5 to 44.5) | 0.6 (-39.2 to 40.4) |
| Day 180 | -6.8 (-51.7 to 38.1) | -12.6 (-46.6 to 21.3) |
Percentage change in total cholesterol from baseline to subsequent visits up to Day 720
| Percentage Change | Part 2 - Placebo-Inclisiran | Part 2 - Inclisiran-Inclisiran |
|---|---|---|
| Day 270 | -7.4 ± 34.80 | -4.8 ± 27.31 |
| Day 330 | -10.9 ± 27.67 | -1.0 ± 39.20 |
| Day 450 | -4.2 ± 22.45 | -2.2 ± 36.05 |
| Day 510 | -6.4 ± 25.37 | 2.8 ± 46.77 |
| Day 630 | -11.9 ± 17.58 | -4.8 ± 33.84 |
| Day 690 | -6.2 ± 26.71 | -1.9 ± 33.83 |
| Day 720 | -11.2 ± 21.86 | -2.9 ± 36.70 |
Absolute Change in total cholesterol from baseline to subsequent visits up to Day 720
| mg/dL | Part 2 - Placebo-Inclisiran | Part 2 - Inclisiran-Inclisiran |
|---|---|---|
| Day 270 | -24.9 ± 154.60 | -13.3 ± 90.68 |
| Day 330 | -35.6 ± 127.19 | -13.0 ± 115.59 |
| Day 450 | -7.9 ± 107.22 | -14.4 ± 113.71 |
| Day 510 | -17.8 ± 120.40 | 0.1 ± 128.73 |
| Day 630 | -44.5 ± 71.81 | -14.9 ± 111.50 |
| Day 690 | -21.6 ± 118.21 | -6.9 ± 114.58 |
| Day 720 | -40.4 ± 93.21 | -8.5 ± 126.48 |
Percentage change in Apolipoprotein B (apoB) from baseline to subsequent visits up to Day 180 demonstrated by Mixed Model Repeated Measures statisitical method.
| Percentage change | Part 1 - Placebo | Part 1 - Inclisiran |
|---|---|---|
| Day 90 | 6.3 (-7.3 to 19.9) | -6.4 (-16.1 to 3.3) |
| Day 150 | 2.8 (-12.5 to 18.1) | -0.7 (-11.8 to 10.3) |
| Day 180 | 4.5 (-8.9 to 17.9) | -5.8 (-15.9 to 4.3) |
Percentage Change in Apolipoprotein B (apoB) from baseline to subsequent visits up to Day 720
| Percentage Change | Part 2 - Placebo-Inclisiran | Part 2 - Inclisiran-Inclisiran |
|---|---|---|
| Day 270 | -0.6 ± 40.91 | -3.3 ± 28.67 |
| Day 330 | -7.9 ± 28.56 | -3.6 ± 34.35 |
| Day 450 | -1.3 ± 21.62 | -3.5 ± 35.66 |
| Day 510 | -3.7 ± 24.21 | 1.9 ± 44.49 |
| Day 630 | -7.3 ± 17.81 | -6.6 ± 32.97 |
| Day 690 | -3.7 ± 27.16 | -5.8 ± 32.38 |
| Day 720 | -10.4 ± 19.68 | -8.0 ± 31.93 |
Absolute change in Apolipoprotein B (apoB) from baseline to subsequent visits up to Day 180
| mg/dL | Part 1 - Placebo | Part 1 - Inclisiran |
|---|---|---|
| Day 90 | 10.0 (-14.5 to 34.5) | -9.4 (-26.8 to 8.0) |
| Day 150 | 3.3 (-24.9 to 31.6) | -1.4 (-21.9 to 19.0) |
| Day 180 | 8.4 (-16.5 to 33.3) | -7.4 (-26.2 to 11.4) |
Absolute Change in Apolipoprotein B (Apo B) from baseline to subsequent visits up to Day 720
| mg/dL | Part 2 - Placebo-Inclisiran | Part 2 - Inclisiran-Inclisiran |
|---|---|---|
| Day 270 | -1.3 ± 83.72 | -1.9 ± 51.79 |
| Day 330 | -11.5 ± 66.78 | -7.3 ± 56.52 |
| Day 450 | 3.0 ± 53.54 | -6.9 ± 61.89 |
| Day 510 | -3.5 ± 58.45 | 1.1 ± 70.40 |
| Day 630 | -15.4 ± 38.17 | -10.1 ± 57.06 |
| Day 690 | -10.6 ± 61.77 | -10.3 ± 54.82 |
| Day 720 | -22.1 ± 45.29 | -13.0 ± 55.14 |
Percentage change in non-HDL-C levels from baseline to subsequent visits up to Day 180
| Percentage change | Part 1 - Placebo | Part 1 - Inclisiran |
|---|---|---|
| Day 90 | 2.9 (-12.4 to 18.2) | -7.2 (-18.1 to 3.6) |
| Day 150 | -1.7 (-19.9 to 16.6) | 1.3 (-11.9 to 14.5) |
| Day 180 | -1.1 (-15.6 to 13.3) | -6.2 (-17.1 to 4.7) |
Percentage Change in non-HDL-C from Baseline to subsequent visits up to Day 720
| Percentage Change | Part 2 - Placebo-Inclisiran | Part 2 - Inclisiran-Inclisiran |
|---|---|---|
| Day 270 | -8.4 ± 39.76 | -7.6 ± 30.95 |
| Day 330 | -13.1 ± 31.27 | -2.3 ± 45.56 |
| Day 450 | -5.5 ± 25.49 | -3.1 ± 43.73 |
| Day 510 | -8.0 ± 28.00 | 2.0 ± 55.28 |
| Day 630 | -13.6 ± 18.88 | -6.5 ± 40.16 |
| Day 690 | -6.4 ± 30.12 | -3.6 ± 40.11 |
| Day 720 | -12.3 ± 23.99 | -5.0 ± 43.40 |
Absolute change in non-HDL-C levels from Baseline to subsequent visits up to Day 180
| mg/dL | Part 1 - Placebo | Part 1 - Inclisiran |
|---|---|---|
| Day 90 | 3.8 (-40.3 to 47.8) | -15.3 (-46.5 to 15.9) |
| Day 150 | -11.6 (-66.4 to 43.3) | 0.6 (-39.1 to 40.3) |
| Day 180 | -5.7 (-50.2 to 38.9) | -12.7 (-46.4 to 21.0) |
Absolute Change in non-HDL Cholesterol (non-HDL-C) from Baseline to Subsequent Visits up to Day 720
| mg/dL | Part 2 - Placebo-Inclisiran | Part 2 - Inclisiran-Inclisiran |
|---|---|---|
| Day 270 | -24.7 ± 157.98 | -17.1 ± 86.34 |
| Day 330 | -37.2 ± 127.12 | -13.9 ± 114.51 |
| Day 450 | -8.8 ± 109.91 | -15.8 ± 112.63 |
| Day 510 | -19.3 ± 120.58 | -2.4 ± 128.45 |
| Day 630 | -43.8 ± 70.56 | -14.7 ± 112.04 |
| Day 690 | -21.0 ± 116.12 | -7.8 ± 114.44 |
| Day 720 | -38.9 ± 91.89 | -9.3 ± 127.46 |
Individual Responsiveness of Subjects defined as the number of subjects reaching on treatment LDL-C levels of \<25 mg/dL, \<50 mg/dL, \<70 mg/dL, and \<100 mg/dL up to Day 180
| Participants | Part 1 - Placebo | Part 1 - Inclisiran |
|---|---|---|
| <25 mg/dL- Day 150 | 0 | 0 |
| <50 mg/dL- Day 150 | 1 | 0 |
| <70 mg/dL- Day 150 | 1 | 2 |
| <100 mg/dL- Day 150 | 1 | 5 |
| >= 100 mg/dL- Day 150 | 17 | 29 |
| <25 mg/dL- Day 180 | 0 | 0 |
| <50 mg/dL- Day 180 | 0 | 1 |
| <70 mg/dL- Day 180 | 0 | 2 |
| <100 mg/dL- Day 180 | 0 | 5 |
| >= 100 mg/dL- Day 180 | 19 | 26 |
Individual Responsiveness of Subjects defined as the number of subjects reaching on treatment LDL-C levels of \<25 mg/dL, \<50 mg/dL, \<70 mg/dL, and \<100 mg/dL up to Day 720
| Participants | Part 2 - Placebo-Inclisiran | Part 2 - Inclisiran-Inclisiran |
|---|---|---|
| <25 mg/dL- Day 330 | 0 | 0 |
| <50 mg/dL- Day 330 | 1 | 0 |
| <70 mg/dL- Day 330 | 2 | 1 |
| <100 mg/dL- Day 330 | 2 | 5 |
| >= 100 mg/dL- Day 330 | 14 | 20 |
| <25 mg/dL- Day 510 | 0 | 0 |
| <50 mg/dL- Day 510 | 0 | 2 |
| <70 mg/dL- Day 510 | 0 | 3 |
| < 100 mg/dL- Day 510 | 1 | 5 |
| >= 100 mg/dL- Day 510 | 16 | 25 |
| <25 mg/dL- Day 690 | 0 | 0 |
| <50 mg/dL- Day 690 | 0 | 0 |
| <70 mg/dL- Day 690 | 0 | 1 |
| <100 mg/dL- Day 690 | 1 | 2 |
| >= 100 mg/dL- Day 690 | 13 | 20 |
| <25 mg/dL- Day 720 | 0 | 0 |
| <50 mg/dL- Day 720 | 0 | 1 |
| <70 mg/dL- Day 720 | 1 | 1 |
| <100 mg/dL- Day 720 | 1 | 5 |
| >= 100 mg/dL- Day 720 | 17 | 22 |
Number of participants in each group who attain global lipid targets for their indication
| Participants | Part 1 - Placebo | Part 1 - Inclisiran |
|---|---|---|
| Day 150 | 1 | 3 |
| Day 180 | 0 | 3 |
Number of participants in each group who attain global lipid targets for their indication
| Participants | Part 2 - Placebo-Inclisiran | Part 2 - Inclisiran-Inclisiran |
|---|---|---|
| Day 330 | 2 | 2 |
| Day 510 | 0 | 4 |
| Day 690 | 0 | 1 |
| Day 720 | 1 | 2 |
Proportion of subjects in each group with ≥20% or ≥30% LDL-C reduction from Baseline in Part 1 (Days 90, 150, 180)
| Participants | Part 1 - Inclisiran | Part 1 - Placebo |
|---|---|---|
| LDL-C >=20%: Day 90 | 4 | 14 |
| LDL-C >=20%: Day 150 | 3 | 9 |
| LDL-C >=20%: Day 180 | 3 | 12 |
| LDL-C >=30%: Day 90 | 3 | 13 |
| LDL-C >=30%: Day 150 | 3 | 6 |
| LDL-C >=30%: Day 180 | 2 | 10 |
Proportion of subjects in each group with ≥20% or ≥30% LDL-C reduction from Baseline in Part 2 (Days 330, 510, 690, and 720)
| Participants | Part 2 - Placebo-Inclisiran | Part 2 - Inclisiran-Inclisiran |
|---|---|---|
| LDL-C >=20%: Day 330 | 5 | 13 |
| LDL-C >=20%: Day 510 | 6 | 11 |
| LDL-C >=20%: Day 690 | 8 | 11 |
| LDL-C >=20%: Day 720 | 7 | 13 |
| LDL-C >=30%: Day 330 | 4 | 8 |
| LDL-C >=30%: Day 510 | 4 | 9 |
| LDL-C >=30%: Day 690 | 4 | 5 |
| LDL-C >=30%: Day 720 | 5 | 8 |
Percentage Change in HDL-C levels (mg/dL) from baseline to subsequent visits on Day 90, 150, and 180
| Percentage change | Part 1 - Placebo | Part 1 - Inclisiran |
|---|---|---|
| Day 90 | -1.1 (-8.6 to 6.5) | 1.4 (-4.0 to 6.7) |
| Day 150 | 2.3 (-8.0 to 12.6) | 3.6 (-3.9 to 11.1) |
| Day 180 | -1.9 (-9.8 to 6.0) | 1.5 (-4.5 to 7.6) |
Percentage change in LDL-C levels from Baseline to Subsequent Visits up to Day 720
| Percentage change | Part 2 - Placebo-Inclisiran | Part 2 - Inclisiran-Inclisiran |
|---|---|---|
| Day 330 | 3.2 ± 13.09 | 4.3 ± 16.45 |
| Day 450 | 1.6 ± 12.26 | 4.8 ± 17.81 |
| Day 510 | 2.9 ± 19.83 | 7.9 ± 17.75 |
| Day 630 | -2.0 ± 14.81 | 0.5 ± 15.81 |
| Day 690 | -2.4 ± 19.17 | 4.5 ± 20.31 |
| Day 720 | -3.6 ± 14.90 | 4.1 ± 16.99 |
Absolute Change in HDL-C levels (mg/dL) from baseline to subsequent visits on Day 90, 150, and 180
| mg/dL | Part 1 - Placebo | Part 1 - Inclisiran |
|---|---|---|
| Day 90 | -0.0 (-3.4 to 3.4) | 0.2 (-2.2 to 2.6) |
| Day 150 | 1.0 (-3.5 to 5.4) | -0.0 (-3.2 to 3.2) |
| Day 180 | -1.2 (-4.5 to 2.1) | 0.0 (-2.5 to 2.5) |
Absolute change in LDL-C levels from Baseline to Subsequent Visits up to Day 720
| mg/dL | Part 2 - Placebo-Inclisiran | Part 2 - Inclisiran-Inclisiran |
|---|---|---|
| Day 330 | 1.6 ± 6.05 | 0.9 ± 6.85 |
| Day 450 | 0.9 ± 6.04 | 1.4 ± 8.53 |
| Day 510 | 1.5 ± 8.78 | 2.5 ± 7.86 |
| Day 630 | -0.7 ± 7.35 | -0.2 ± 7.70 |
| Day 690 | -0.6 ± 9.57 | 1.0 ± 8.31 |
| Day 720 | -1.5 ± 7.22 | 0.8 ± 7.34 |
Absolute Change in VLDL-C levels from baseline to subsequent visits on Days 90, 150, and 180
| mg/dL | Part 1 - Placebo | Part 1 - Inclisiran |
|---|---|---|
| Day 90 | 0.6 (-2.8 to 4.0) | 1.6 (-0.9 to 4.0) |
| Day 150 | 3.0 (-1.3 to 7.3) | 0.4 (-2.7 to 3.4) |
| Day 180 | 1.8 (-3.0 to 6.5) | 1.5 (-2.1 to 5.1) |
Absolute change in VLDL-C levels from Baseline to Subsequent Visits up to Day 720
| mg/dL | Part 2 - Placebo-Inclisiran | Part 2 - Inclisiran-Inclisiran |
|---|---|---|
| Day 330 | 0.0 ± 9.38 | 2.7 ± 8.03 |
| Day 450 | 1.1 ± 5.84 | 4.4 ± 8.91 |
| Day 510 | -0.9 ± 4.76 | -0.2 ± 8.85 |
| Day 630 | 6.7 ± 13.76 | 0.2 ± 8.39 |
| Day 690 | 6.9 ± 14.58 | 0.8 ± 9.34 |
| Day 720 | 2.5 ± 6.81 | 1.7 ± 9.06 |
Percentage Change in VLDL-C levels (mg/dL) from baseline to subsequent visits on Days 90, 150, and 180
| Percentage change | Part 1 - Placebo | Part 1 - Inclisiran |
|---|---|---|
| Day 90 | 0.6 (-17.4 to 18.7) | 11.9 (-1.0 to 24.9) |
| Day 150 | 16.3 (-1.6 to 34.1) | 4.9 (-7.8 to 17.6) |
| Day 180 | 10.0 (-13.4 to 33.5) | 12.3 (-5.3 to 29.9) |
Percentage change in VLDL-C levels from Baseline to Subsequent Visits up to Day 720
| Percentage Change | Part 2 - Placebo-Inclisiran | Part 2 - Inclisiran-Inclisiran |
|---|---|---|
| Day 330 | 6.8 ± 38.92 | 20.8 ± 57.44 |
| Day 450 | 7.1 ± 28.86 | 23.9 ± 46.36 |
| Day 510 | 2.1 ± 33.45 | 7.1 ± 43.16 |
| Day 630 | 25.1 ± 44.22 | 6.2 ± 46.21 |
| Day 690 | 26.5 ± 51.79 | 11.4 ± 59.86 |
| Day 720 | 13.9 ± 33.26 | 12.4 ± 50.37 |
Absolute Change in Apolipoprotein A-1 (Apo-A1) from baseline to subsequent visits on Days 90, 150, and 180
| mg/dL | Part 1 - Placebo | Part 1 - Inclisiran |
|---|---|---|
| Day 90 | 2.6 (-5.2 to 10.3) | 0.6 (-4.9 to 6.1) |
| Day 150 | 4.0 (-6.5 to 14.6) | -1.4 (-9.1 to 6.3) |
| Day 180 | 1.4 (-6.9 to 9.8) | -1.3 (-7.7 to 5.1) |
Absolute change in Apolipoprotein A-1 (Apo-A1) from Baseline to Subsequent Visits up to Day 720
| mg/dL | Part 2 - Placebo-Inclisiran | Part 2 - Inclisiran-Inclisiran |
|---|---|---|
| Day 330 | 0.9 ± 14.14 | 1.2 ± 13.85 |
| Day 450 | 4.9 ± 14.04 | 4.7 ± 16.59 |
| Day 510 | 6.7 ± 20.39 | 7.8 ± 16.32 |
| Day 630 | 5.4 ± 15.59 | 1.3 ± 13.11 |
| Day 690 | 6.9 ± 17.07 | 9.3 ± 15.69 |
| Day 720 | 3.9 ± 15.15 | 6.9 ± 11.30 |
Percentage Change in Apolipoprotein A-1 (Apo-A1) from baseline to subsequent visits on Day 90, 150, and 180
| Percentage change | Part 1 - Placebo | Part 1 - Inclisiran |
|---|---|---|
| Day 90 | 1.6 (-4.5 to 7.6) | 0.6 (-3.7 to 4.9) |
| Day 150 | 3.0 (-5.1 to 11.1) | 0.4 (-5.5 to 6.3) |
| Day 180 | 1.6 (-5.0 to 8.3) | -1.0 (-6.1 to 4.1) |
Percentage change in Apolipoprotein A-1 (Apo-A1) from Baseline to Subsequent Visits up to Day 720
| Percentage change | Part 2 - Placebo-Inclisiran | Part 2 - Inclisiran-Inclisiran |
|---|---|---|
| Day 330 | 0.4 ± 11.37 | 1.3 ± 10.80 |
| Day 450 | 4.4 ± 10.76 | 3.9 ± 12.71 |
| Day 510 | 6.2 ± 17.00 | 6.8 ± 13.40 |
| Day 630 | 5.4 ± 11.11 | 0.8 ± 9.93 |
| Day 690 | 5.6 ± 13.92 | 7.2 ± 12.17 |
| Day 720 | 3.5 ± 11.71 | 5.5 ± 9.27 |
Percentage Change in Lp(a) from Baseline to Subsequent Visits up to Day 180
| Percentage change | Part 1 - Placebo | Part 1 - Inclisiran |
|---|---|---|
| Day 90 | 4.3 (-6.2 to 14.7) | -4.6 (-12.2 to 2.9) |
| Day 150 | 15.2 (-6.8 to 37.2) | -3.8 (-19.8 to 12.2) |
| Day 180 | 4.9 (-6.5 to 16.4) | -4.8 (-13.5 to 4.0) |
Percentage change in Lp(a) from Baseline to Subsequent Visits up to Day 720
| Percentage change | Part 2 - Placebo-Inclisiran | Part 2 - Inclisiran-Inclisiran |
|---|---|---|
| Day 330 | 2.5 ± 33.15 | -1.4 ± 26.69 |
| Day 450 | 3.4 ± 45.12 | 0.2 ± 26.42 |
| Day 510 | 8.3 ± 44.74 | 13.4 ± 39.37 |
| Day 630 | -8.4 ± 32.65 | 1.7 ± 29.43 |
| Day 690 | -10.7 ± 34.02 | -5.3 ± 27.44 |
| Day 720 | -11.4 ± 51.06 | -3.1 ± 45.08 |
Absolute Change in Lp(a) from baseline to subsequent visits up to Day 180
| nmol/L | Part 1 - Placebo | Part 1 - Inclisiran |
|---|---|---|
| Day 90 | 5.8 (-9.4 to 20.9) | -3.8 (-14.7 to 7.1) |
| Day 150 | 3.9 (-12.8 to 20.6) | -5.6 (-17.7 to 6.5) |
| Day 180 | 1.2 (-12.4 to 14.7) | -5.1 (-15.3 to 5.2) |
Absolute change in Lp(a) from Baseline to Subsequent Visits up to Day 720
| nmol/L | Part 2 - Placebo-Inclisiran | Part 2 - Inclisiran-Inclisiran |
|---|---|---|
| Day 330 | -3.1 ± 36.71 | -5.2 ± 30.65 |
| Day 450 | -3.8 ± 47.48 | 3.1 ± 41.28 |
| Day 510 | 14.5 ± 50.25 | 18.4 ± 53.31 |
| Day 630 | -2.4 ± 31.18 | 13.7 ± 50.77 |
| Day 690 | -5.3 ± 26.52 | 5.8 ± 26.46 |
| Day 720 | -6.0 ± 48.12 | 5.2 ± 30.44 |
Percent change in hsCRP from Baseline to subsequent visits up to Day 180
| Percentage Change | Part 1 - Inclisiran | Part 1 - Placebo |
|---|---|---|
| Day 90 | 41.2 ± 243.94 | 42.0 ± 170.41 |
| Day 150 | 230.8 ± 640.11 | 126.9 ± 380.15 |
| Day 180 | 115.1 ± 490.17 | 45.2 ± 143.24 |
Percentage change in hsCRP from baseline to subsequent visits up to Day 720
| Percentage Change | Part 2 - Placebo-Inclisiran | Part 2 - Inclisiran-Inclisiran |
|---|---|---|
| Day 330 | 178.9 ± 657.67 | 17.3 ± 73.29 |
| Day 510 | 266.7 ± 936.76 | 64.7 ± 204.54 |
| Day 690 | 29.0 ± 125.18 | 37.5 ± 92.40 |
| Day 720 | 49.6 ± 167.16 | 38.60 ± 112.57 |
Absolute Change in High-Sensitivity C-Reactive Protein (hsCRP) from Baseline to subsequent visits up to Day 180
| mg/L | Part 1 - Placebo | Part 1 - Inclisiran |
|---|---|---|
| Day 90 | -3.2 ± 9.46 | 0.7 ± 4.25 |
| Day 150 | 0.5 ± 15.07 | 1.1 ± 6.51 |
| Day 180 | -3.8 ± 9.33 | 0.2 ± 3.75 |
Absolute Change in High-Sensitivity C-Reactive Protein (hsCRP) from baseline to subsequent visits up to Day 720
| mg/L | Part 2 - Placebo-Inclisiran | Part 2 - Inclisiran-Inclisiran |
|---|---|---|
| Day 330 | -4.0 ± 9.98 | -0.4 ± 2.81 |
| Day 510 | -3.4 ± 10.07 | 0.9 ± 4.75 |
| Day 690 | -4.7 ± 10.21 | 0.7 ± 3.94 |
| Day 720 | -3.7 ± 9.86 | -0.2 ± 4.25 |
Percentage change in Apo-B from baseline to Day 150 as demonstrated using the ANCOVA statisitical model.
| Percentage change | Part 1 - Placebo | Part 1 - Inclisiran |
|---|---|---|
| Percent Change in Apo-B From Baseline to Day 150 | 3.55 (-13.60 to 20.71) | -0.75 (-11.50 to 9.99) |
Percentage Change in non-HDL-C from baseline to Day 150 as demonstrated using the ANCOVA statisitical model.
| Percentage Change | Part 1 - Placebo | Part 1 - Inclisiran |
|---|---|---|
| Percent Change in Non-HDL-C From Baseline to Day 150 | 2.46 (-19.12 to 24.05) | 0.37 (-12.68 to 13.42) |
Percentage change in total cholesterol from baseline to Day 150 as demonstrated using the ANCOVA statisitical model.
| Percentage Change | Part 1 - Placebo | Part 1 - Inclisiran |
|---|---|---|
| Percent Change in Total Cholesterol From Baseline to Day 150 | 1.51 (-16.49 to 19.50) | 0.71 (-10.39 to 11.82) |
Number of participants in each group with ≥30% LDL-C reduction from baseline at Day 150 using the Regression Logistic Statistical Model
| Participants | Part 1 - Placebo | Part 1 - Inclisiran |
|---|---|---|
| Proportion of Subjects With ≥30% LDL-C Reduction of From Baseline at Day 150 | 3 | 6 |
Collected over Adverse Events were collected from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of approximately 2 years.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Inclisiran | 0/37 (0%) | 2/37 (5.4%) | 12/37 (32.4%) |
| Part 1: Placebo | 0/19 (0%) | 1/19 (5.3%) | 6/19 (31.6%) |
| Part 1:All Patients | 0/56 (0%) | 3/56 (5.4%) | 18/56 (32.1%) |
| Part 2: Inclisiran | 3/53 (5.7%) | 11/53 (20.8%) | 29/53 (54.7%) |
| Event | Part 1: Inclisiran | Part 1: Placebo | Part 1:All Patients | Part 2: Inclisiran |
|---|---|---|---|---|
| Family stressSocial circumstances | 0/37 | 1/19 | 1/56 | 0/53 |
| Aortic valve stenosisCardiac disorders | 0/37 | 0/19 | 0/56 | 2/53 |
| Pneumonia viralInfections and infestations | 0/37 | 0/19 | 0/56 | 2/53 |
| Non-cardiac chest painGeneral disorders | 1/37 | 0/19 | 1/56 | 0/53 |
| EndocarditisInfections and infestations | 1/37 | 0/19 | 1/56 | 1/53 |
| Adenocarcinoma of colonNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/37 | 0/19 | 1/56 | 0/53 |
| Angina unstableCardiac disorders | 0/37 | 0/19 | 0/56 | 1/53 |
| Arteriosclerosis coronary arteryCardiac disorders | 0/37 | 0/19 | 0/56 | 1/53 |
| Cardiac failureCardiac disorders | 0/37 | 0/19 | 0/56 | 1/53 |
| Coronary artery diseaseCardiac disorders | 0/37 | 0/19 | 0/56 | 1/53 |
| Event | Part 1: Inclisiran | Part 1: Placebo | Part 1:All Patients | Part 2: Inclisiran |
|---|---|---|---|---|
| Respiratory tract infection viralInfections and infestations | 2/37 | 2/19 | 4/56 | 2/53 |
| Corona virus infectionInfections and infestations | 0/37 | 0/19 | 0/56 | 4/53 |
| International normalised ratio increasedInvestigations | 0/37 | 0/19 | 0/56 | 3/53 |
| DiarrhoeaGastrointestinal disorders | 2/37 | 0/19 | 2/56 | 0/53 |
| PyrexiaGeneral disorders | 2/37 | 0/19 | 2/56 | 0/53 |
| AnaemiaBlood and lymphatic system disorders | 1/37 | 1/19 | 2/56 | 1/53 |
| AstheniaGeneral disorders | 0/37 | 1/19 | 1/56 | 0/53 |
| PharyngitisInfections and infestations | 0/37 | 1/19 | 1/56 | 0/53 |
| TonsillitisInfections and infestations | 1/37 | 1/19 | 2/56 | 0/53 |
| Alanine aminotransferase increasedInvestigations | 0/37 | 1/19 | 1/56 | 1/53 |
| Age, Categorical(Participants) | Inclisiran | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 34 | 19 | 53 |
| >=65 years | 3 | 0 | 3 |
| Sex: Female, Male(Participants) | Inclisiran | Placebo | Total |
|---|---|---|---|
| Female | 23 | 11 | 34 |
| Male | 14 | 8 | 22 |
| Race (NIH/OMB)(Participants) | Inclisiran | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 6 | 2 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 31 | 17 | 48 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Ran from Feb 2019 to primary completion in Mar 2020, 12 months.
Results were first posted in Nov 2022, 2 years 8 months after primary completion. A results delay was requested in Nov 2020.
Of 20 phase 3 interventional studies under Homozygous Familial Hypercholesterolemia, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 34. This study's 12 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Inclisiran
Homozygous Familial Hypercholesterolemia →